Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls- eight years follow-up of IBS patients in primary care

BMC Public Health

Toomas Timpka³  Claes Hallert¹  Ewa Grodzinsky²  Åshild Faresjö³ 

[1] Department of Social and Welfare Studies, Linköping University, Linköping, Sweden;Unit of Research and development , County Council of Östergötland, Linköping, Department of Medicine and Health, Drug Research, Linkoping University, Linköping, Sweden;Department of Medicine and Health, Community Medicine, Linköping University, Linköping, Sweden

关键词: Gender;    Disease worry;    Public health problem;    Case–control;    Co-morbidity;    Functional gastrointestinal disorder;   

Others  :  1161801
DOI  :  10.1186/1471-2458-13-832

 received in 2012-12-04, accepted in 2013-08-30,  发布年份 2013

【 摘 要 】

Background

Irritable Bowel Syndrome (IBS) is a hidden public health disease that affects up to 20% of the general population. Although co-morbidity can affect diagnose setting and treatment of the disease, there are few studies concerning diagnosed and registered co-morbidity for IBS patients in primary care. The aim of this study was to analyse co-morbidity among IBS-patients compared to age- and sex-matched controls from the general population using data from a county-wide computerized medical record system.

Methods

IBS cases were recruited from three Swedish primary health care centres during a five-years period and controls from the same corresponding geographical areas. Co-morbidity data for IBS-patients and morbidity data for controls were derived from a population-based Health Care Register (HCR) covering all diagnoses in primary as well as hospital care in the region. Odds Ratios with 95% confidence intervals for morbidity in gastro-intestinal and non-gastrointestinal diagnoses for cases with irritable bowel syndrome compared to controls were calculated separately for each gender and diagnosis.

Results

We identified more co-morbidity among IBS patients of both sexes, compared to matched controls in the general population. Patients with IBS were particularly more worried about having a serious disease than their control group. The risk among male IBS-cases to get this latter diagnose was three times higher compared to the male controls.

Conclusions

In this population based case–control study, the analysis of diagnoses from the HCR revealed a broad spectrum of common co-morbidity and significantly more physician-recorded diagnoses among IBS-patients in comparisons to the control group.

【 授权许可】

   
2013 Faresjö et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Choung RS, Locke GR III: Epidemiology of IBS. Gastroenterol Clin North Am 2011, 40:1-10.
• [2]Spiegel BM: The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009, 11:265-269.
• [3]Drossman DA: The functional gastrointestinal disorders. Rome II. 2nd edition. VA, USA: Degnon associates, Mclean; 2000.
• [4]El Serag HB, Olden K, Bjorkman D: Health-related quality of life among persons with irritable bowel syndrome a systematic review. Aliment Pharmacol Ther 2002, 16:1171-1185.
• [5]Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Åkerlind I: A population based case–control study of work and psychosocial problems in patients with irritable bowel syndrome-women are more seriously affected than men. Am J Gastroenterol 2007, 102(2):371-379.
• [6]Herschbach P, Henrich G, von Rad M: Psychological factors in functional gastrointestinal disorders: characteristics of the disorder or of the illness behaviour? Psychosom Med 1999, 61:148-153.
• [7]Koloski NA, Talley NJ, Boyce PM: Predictors of health care seeking for irritable bowel syndrome and non-ulcer dyspepsia: a critical review of the literature on symptoms and psychological factors. Am J Gastroenterol 2001, 96:1340-1349.
• [8]Kettel J, Jones R, Lydiard S: Reasons for consultation in irritable bowel syndrome: symptoms and patients characteristics. Br J Gen Pract 1992, 42:459-461.
• [9]Van Dulmen AM, Fennis JEM, Mokkink HGA, Van der Velden HGM, Bleijenberg G: Doctor’s perceptions of patient’s cognitions and complaints in irritable bowel syndrome at an out-patients clinic. J Psychosom Res 1994, 38:581-590.
• [10]Talley NJ, Spiller R: Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002, 360:555-564.
• [11]Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM: Effects of stressful life events on bowel syndrome compared with subjects without bowel dysfunction. Gut 1992, 33:825-830.
• [12]Mertz H, Naliboff B, Munkata J, Niazi N, Mayer EA: Altered rectal perceptions are a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109:40-52.
• [13]Heymann-Mönnikes I, Arnold R, Florin I, Herda C, Melfsen S, Mönnikes H: The combinations of medical treatment plus multicomponent behavioural therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000, 95:981-994.
• [14]Guthrie E, Creed F, Dawson D, Tomenson B: A randomized trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993, 163:315-321.
• [15]Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Foldevi M: Patients with irritable bowel syndrome in Swedish primary care. Eur J Gen Pract 2006, 12:88-90.
• [16]Faresjö A, Grodzinsky E, Foldevi M, Johansson S, Wallander MA: Patients with IBS in primary care appear not to be heavy health care utilisers. Aliment Pharmacol Ther 2006, 23(6):807-811.
• [17]Markowitz M, Harris W, Ricci JF, Harrison C, Gordon SH, Wentz A: Comorbid conditions in patients with irritable bowel syndrome: data from a national IBS awareness registry. Gastroenterology 2001, 120(suppl1):105.
• [18]Hudson JI, Goldenberg DL, Pope HG, Keck PE, Schlesinger L: Co-morbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992, 92:363-367.
• [19]Longstreth GF, Wolde-Tsadik G: Irritable bowel –type symptoms in HMO examinees; prevalence, demographics, and clinical correlates. Dig Dis Sci 1993, 38:1581-1589.
• [20]Sperber AD, Carmel S, Atzmon Y, Weisberg I, Shalit Y, Neuman L, Fich A, Friger M, Buskila D: Use of the functional bowel disorder severity index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000, 95:995-998.
• [21]Walker EA, Gelfand AN, Gelfand MD, Green C, Katon WJ: Chronic pelvic pain and gynaecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gyneacol 1996, 17:39-46.
• [22]Sperber AD, Carmel S, Atzmon Y, Weisberg I, Shalit Y, Neuman L, Fich A, Buskila D: The sense of coherence index and the irritable bowel syndrome: a cross-sectional comparison among irritable bowel syndrome patients with and without coexisting fibromyalgia, irritable bowel syndrome non-patients, and controls. Scand J Gastroenterol 1999, 34:259-263.
• [23]Jones R, Lationovic J, Charlton J, Gulliford M: Psysical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the general practice research database. Aliment Pharmacol Ther 2006, 24:879-886.
• [24]Vandvik PO, Lydersen S, Farup PG: Prevalence, co morbidity and impact of irritable bowel syndrome in Norway. Scand J Gastroenterol 2006, 41:650-656.
• [25]Engsbro AL, Simrèn M, Bytzer P: The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterol Motil 2012, 24:604-611. E266
• [26]Wiréhn AB, Karlsson M, Carstensen J: Estimating disease prevalence using a population-based administrative health care database. Scand J Public Health 2007, 35:424-431.
• [27]Whithead WE, Palsson O, Jones KR: Systematic review of the co-morbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002, 122:1140-1156.
• [28]Mearin F, Badia X, Balboa A, Benavent J, Caballeros AM, Domìnguez-Munoz E, Garrigues V, Pique JM, Roset M, Cucala M, Figueras M: RITMO group: predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients. Aliment Pharmacol Ther 2006, 23:815-826.
• [29]Vandevik PO, Wilhelmsen I, Ihlebäck C, Farup PG: Co-morbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004, 20:1195-1203.
• [30]Singh P, Agnihotri A, Pathak MK, Shirazi A, Tiwari RP, Sreenivas V, Sagar R, Makharia GK: Psychiatric, somatic and functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. J Neurogastroenterol Motil 2012, 18(3):324-331.
• [31]Maclean EW, Palsson OS, Turner MJ, Whitehead WE: Development and validation of new disease-specific measures of somatisation and co-morbidity in IBS. J Psychosom Res 2012, 73:352-355.
• [32]Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, Mönnikes H: Somatic co-morbidities of irritable bowel syndrome: A systematic analysis. J Psychosom Res 2008, 64:573-582.
• [33]Haug Tangen T, Mykletun A, Dahl A: Are anxiety and depression related to gastrointestinal symptoms in the general populations? Scand J Gastroenterol 2002, 37:294-298.
• [34]Drossman DA, McKee DC, Sandler RS: Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and non-patients with irritable bowel syndrome. Gastroenterology 1988, 95:701-708.
• [35]Olden KW, Drossman DA: Psychological and psychiatric aspects of gastrointestinal disease. Med Clin North Am 2000, 84:1313-1327.
• [36]Fass R, Fullerton S, Tung S, Mayer EA: Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol 2000, 95:1195-1200.
• [37]Jarett M, Heitkemper M, Cain KC, Burr RL, Hertig V: Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Dig Dis Sci 2000, 45:952-959.
• [38]Lee S, Wu J, Ma L, Tsang A, Guo WJ, Sung J: Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009, 30:643-651.
• [39]Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Åkerlind I: Psychosocial factors at work and in everyday life are associated with irritable bowel syndrome. Eur J Epidemiol 2007, 22(7):473-480.
• [40]Carter RM, Wittchen H, Pfister H, Kessler RC: One-year prevalence of subthreshold and threshold DSM-IV. Generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001, 13:78-88.
• [41]Den Boer JA, Bosker FJ, Slaap BR: Serotonergic drugs in the treatment of depressive and anxiety disorders. Hum Psychopharmacol 2000, 15:315-336.
• [42]Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM: Serotonin: a review. J Vet Pharmocol Ther 2008, 31:187-199.
• [43]Chang F, Lu CL: Irritable bowel syndrome and migraine; bystanders or partners? J Neurogastenterol Motil 2013, 19:301-311.
• [44]Azpiroz F, Dapoigny M, Pace F, Müller-Lissner S, Coremans G, Whorwell P, Stockbrugger RW, Smout A: Nongastrointestinal disorders in the irritable bowel syndrome. Digestion 2000, 62:66-72.
• [45]Guthrie EA, Creed FH, Whorwell PJ, Tomenson B: Outpatients with irritable bowel syndrome: a comparison of first time and chronic attenders. Gut 1992, 33:361-363.
• [46]Mulak A, Paradowski L: Migraine and irritable bowel syndrome. Neurol Neurochir Pol 2005, 39(suppl):S55-S60.
• [47]Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D: Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gatroenterol 1999, 94:3541-3546.
• [48]Sloth H, Jörgensen LS: Predictors for the course of chronic non-organic upper abdominal pain. Scand J Gastroenterol 1989, 24:440-444.
• [49]Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA: Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC gastroenterol 2006, 6:26. BioMed Central Full Text
• [50]Vos DM: Joint involvement associated with inflammatory bowel disease. Dig Dis 2009, 27:511-515.
• [51]Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Faresjö T, Timpka T: Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. JCMP 2008, 14(9):870-877.
• [52]Wessely S, Nimnuan C, Sharpe M: Functional somatic syndromes: one or many? Lancet 1999, 354:936-939.
• [53]Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M: Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006, 51:2113-2120.
• [54]Abrahamsson H: Gastrointestinal motility in patients with the irritable bowel syndrome. Scand J Gastroenterol 1987, 130:21-26.
• [55]Simrèn M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES: Quality of life in inflammatory bowel disease in remisson: the impact of IBS-like symptom and associated psychological factors. Am J Gastroenterol 2002, 97:389-396.
• [56]Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005, 34:235-245.
• [57]Quigley EM: Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dis 2005, 6:122-132.
• [58]Swedish National Board of Health and Welfare: Patient register. The Hospital Discharge Register. Discharges 1964–2002, Quality and Content. Stockholm: Swedish National Board of Health and Welfare; 2004.
• [59]Wilchesky M, Tamblyn RM, Huang A: Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004, 57:131-141.
• [60]Hjerpe P, Merlo J, Ohlsson H, Bengtsson Boström K, Lindblad U: Validity of registration of ICD codes and prescriptions in a research database in Swedish primary care: a cross-sectional study in Skaraborg primary care database. BMC Med Inform Decis Mak 2010, 10:23. BioMed Central Full Text
• [61]Knol MJ, Vandenbroucke JP, Scott P, Egger M: What do case–control studies estimate? Survey of methods and assumptions in published case–control research. Am J Epidemiol 2008, 168:91073-91081.
• [62]Bellini M, Tosetti C, Costa F, Biagi S, Stasi C, Del Punta A, Marchi S: The general practitioner’s approach to irritable bowel syndrome: From intention to practice. Dig Liver Dis 2005, 37:934-939.
• [63]Talley NJ: When to conduct testing in patients with suspected irritable bowel syndrome. Rev Gastroenterol Dis 2003, 3(suppl):18-24.
• [64]Agreùs L: Rome? Manning? Who care? Am J Gastroenterol 2000, 95(10):2679-2680.
• [65]Arch GM III, Hueston WJ: Using other people’s data: the ins and outs of secondary data analysis. Fam Med 1997, 29(8):568-571.
• [66]Kurland LT, Molgaard CA: The patient record in epidemiology. Sci Am 1981, 245(4):46-55.